Radiofrequency ablation for peribiliary hepatocellular carcinoma: propensity score matching analysis

被引：0
作者：
Cui, Jin [1 ]
Sui, Xinzi [2 ]
Liu, Kaiwen [1 ]
Huang, Min [3 ]
Zheng, Yuanwen [4 ]
Zhao, Xinya [1 ]
Wang, Gongzheng [1 ]
Wang, Ximing [1 ]
机构：
[1] Shandong First Med Univ, Dept Radiol, Shandong Prov Hosp Affiliated, Jinan, Peoples R China
[2] Linyi Peoples Hosp, Dept Radiol, Linyi, Peoples R China
[3] Shandong First Med Univ, Shandong Prov Hosp Affiliated, Dept Lab, Jinan, Peoples R China
[4] Shandong First Med Univ, Shandong Prov Hosp Affiliated, Dept Hepatobiliary Surg, Jinan, Shandong, Peoples R China
来源：
INSIGHTS INTO IMAGING | 2025年 / 16卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Hepatocellular carcinoma; Peribiliary location; Radiofrequency ablation; Therapeutic outcome; GUIDED TUMOR ABLATION; PERCUTANEOUS MICROWAVE ABLATION; BILE-DUCT INJURY; TRANSARTERIAL CHEMOEMBOLIZATION; LIVER-TUMORS; ADJACENT; RESECTION; VESSELS; STRATEGIES; SAFETY;
D O I：
10.1186/s13244-025-01919-5
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
ObjectivesAt present, there are no established clinical guidelines for radiofrequency ablation (RFA) of peribiliary hepatocellular carcinoma (HCC). Therefore, the aim of this study was to compare the long-term outcomes of RFA for peribiliary vs. non-peribiliary HCC.MethodsThis retrospective study included 282 patients with peribiliary HCC (n = 109) or non-peribiliary HCC (n = 173) who received RFA between February 2013 and May 2021. Local tumor progression (LTP), overall survival (OS), disease-free survival (DFS), and complications were compared before and after propensity score matching (PSM).ResultsBefore PSM, there were no significant differences in 5-year LTP rates (26.3% vs. 23.6%, p = 0.602), OS rates (56.6% vs. 68.0%, p = 0.586), or DFS rates (22.9% vs. 25.7%, p = 0.239) between the peribiliary and non-peribiliary groups. After PSM, there were no significant differences in the 1-, 3-, and 5-year LTP rates (13.0%, 23.1%, and 26.3% vs. 12.1%, 25.1%, and 28.2%, respectively, p = 0.857), OS rates (97.2%, 73.5%, and 56.6% vs. 95.3%, 79.5%, and 70.6%, p = 0.727), or DFS rates (59.4%, 29.4%, and 22.9% vs. 64.2%, 33.1%, and 23.8%, p = 0.568) between the peribiliary non-peribiliary groups. Peribiliary location was not a significant prognostic factor for LTP (p = 0.622) or OS (p = 0.587). In addition, mild intrahepatic bile duct dilatation was more frequent in the peribiliary group (9.2% vs. 2.8%, p = 0.045).ConclusionLong-term outcomes of RFA were similar for peribiliary and non-peribiliary HCC. RFA is a viable alternative for treatment of peribiliary HCC.Critical relevance statementThe local tumor progression (LTP), overall survival (OS), and disease-free survival (DFS) rates after radiofrequency ablation (RFA) were similar for peribiliary and non-peribiliary hepatocellular carcinoma (HCC).Key PointsThere are currently no clinical guidelines for radiofrequency ablation (RFA) of peribiliary hepatocellular carcinoma (HCC).Local tumor progression, overall survival, and disease-free survival after RFA were similar for peribiliary and non-peribiliary HCC.RFA is a viable alternative for the treatment of peribiliary HCC.
引用
收藏
页数：13
相关论文
共 72 条
  • [1] EASL clinical practice guidelines: management of hepatocellular carcinoma, J Hepatol, 69, pp. 182-236, (2018)
  • [2] Heimbach J.K., Kulik L.M., Finn R.S., Et al., AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, pp. 358-380, (2018)
  • [3] Ohnishi T., Yasuda I., Nishigaki Y., Et al., Intraductal chilled saline perfusion to prevent bile duct injury during percutaneous radiofrequency ablation for hepatocellular carcinoma, J Gastroenterol Hepatol, 23, pp. e410-e415, (2008)
  • [4] Lin M.X., Ye J.Y., Tian W.S., Et al., Risk factors for bile duct injury after percutaneous thermal ablation of malignant liver tumors: a retrospective case-control study, Dig Dis Sci, 62, pp. 1086-1094, (2017)
  • [5] Kai J., Ming S., Yang L., Et al., Complete radio frequency ablation of hepatocellular carcinoma adjacent to the main bile duct and blood vessels between the first and the second hepatic portal, Cell Biochem Biophys, 66, pp. 397-402, (2013)
  • [6] van Tilborg A.A., Scheffer H.J., de Jong M.C., Et al., MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts, Cardiovasc Intervent Radiol, 39, pp. 1438-1446, (2016)
  • [7] Hu H., Chi J.C., Liu R., Zhai B., Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes, Int J Hyperthermia, 38, pp. 191-201, (2021)
  • [8] Kondo Y., Shiina S., Tateishi R., Et al., Intrahepatic bile duct dilatation after percutaneous radiofrequency ablation for hepatocellular carcinoma: impact on patient’s prognosis, Liver Int, 31, pp. 197-205, (2011)
  • [9] Yang W., Yan K., Wu G.X., Et al., Radiofrequency ablation of hepatocellular carcinoma in difficult locations: strategies and long-term outcomes, World J Gastroenterol, 21, pp. 1554-1566, (2015)
  • [10] Wakamatsu T., Ogasawara S., Chiba T., Et al., Impact of radiofrequency ablation-induced Glisson’s capsule-associated complications in patients with hepatocellular carcinoma, PLoS One, 12, (2017)
12345678